Life Sciences Pennsylvania will be hosting a Making the Most of Your Membership virtual roundtable discussion. This event is designed especially for new LSPA Members or newer employees of LSPA Member companies who are looking for ways to build and improve their life sciences network.

Topics to be covered include:

• How can I position my company as a valuable resource within the life science community?
• The life sciences are a unique industry; what do I need to know, and how do I learn it?
• What specific techniques will help me make the most of my Life Sciences Pennsylvania membership?

Agenda 
8:30 AM – 8:45 AM: Pre-Meeting Networking
8:45 AM – 9:00 AM:  LSPA Welcome
9:00 AM – 10:00 AM: Presentation & Roundtable Discussion

*This event is for Life Sciences Pennsylvania members only. There is no cost to attend, however, attendance is limited and will be first-come, first-serve. Once your registration has been received we will share an invitation to a Zoom Meeting.

Not an LSPA Member? Contact Lois Stephens, Director, Membership at lstephens@lifesciencespa.org to learn more and join.

Pharmacokinetic and pharmacodynamic studies form an important foundation for drug development by profiling therapeutic agents and their effects across multiple timepoints. Unfortunately, PK/PD protein measurements are often limited by plate or bead-based methods with narrow dynamic range, relatively large volume requirements, and long assay times. These factors restrict both the quantity and the quality of proteomic data that can be collected from cell-based or animal models. Correlia offers an automated platform to overcome these bottlenecks – enabling highly efficient protein measurements from as little as 2 microliters of a diluted biosample. In this webinar, we focus on case studies in therapeutic antibody development. Both general and specific measurements of monoclonal antibodies are made possible, respectively based upon IgG-generic and ligand-specific binding affinities.

Key Learnings:

• Protein concentrations can be measured in a fraction of the time and sample volume required for conventional immunoassays.
• Targets are measured in a “sample-in, answer-out” workflow with minimal user intervention.
• Correlia measurements demonstrate extended dynamic range when validated against competing immunoassays.

Company Bio:

Correlia Biosystems seeks to accelerate biopharma development and expand our understanding of health through next-gen protein analysis tools. Correlia immunoassays are based on a proprietary gel nanomaterial that increases the rate of the molecular binding events required for protein measurement. This technology has serviced 5 of the top 15 global pharma companies. Correlia’s first product line consists of immunoassay kits and a corresponding instrument within the deck of a liquid handling robot. Correlia Biosystems won the 2020 Society for Laboratory Automation and Screening IGNITE Award for Best Startup, and their commercial instrument will be introduced at the SLAS 2022 conference.

Website: www.correliabio.com

Speaker Bio:

Samuel Tia is a co-founder and CSO of Correlia Biosystems, where he works with their scientific teams to expand Correlia’s immunoassay test menus and deliver solutions for customer proteomic applications. Dr. Tia received a Ph.D. in Bioengineering from UC Berkeley, where his work in the Herr Lab led to a licensed patent. Prior to graduate studies, he obtained a BS in Mechanical Engineering from the University of Florida and had industry experience in drug delivery and medical-grade manufacturing/packaging.